
Provenge Extends Life of Prostate Cancer Patients, Study Finds
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
ISTO Technologies has received FDA approval to begin a Phase I clinical study for NuQu, an injectable formulation of juvenile cartilage cells designed to treat chronic back pain caused by degenerative disc disease.
Sunshine Heart, a global company that develops cardiac assist devices, has successfully completed the first two implants of the company’s C-Pulse heart assist system under a 20-person clinical trial approved by the U.S. Food and Drug Administration.
Symphony Medical, a developer of novel biopolymer technologies for cardiac disorders, has successfully used its flagship Algisyl-LVR technology to treat their first human patient.
Copyright © 2025 | WordPress Theme by MH Themes